Accueil   Diary - News   All news Theranexus announces that R. BESSERVE will join its board of directors

Theranexus announces that R. BESSERVE will join its board of directors

 

Lyon, 11 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that Rodolphe Besserve, Head of the Start-Ups and French Techs (SuFT Advisory) activity at Société Générale, is joining its Board of Directors as independent director. Mr. Besserve is set to replace the representative of Sofimac Innovation, CEO François Miceli, who is resigning. His appointment will be subject to ratification at the next shareholders’ meeting.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree